Pfizer could shift overseas production to US if Trump's pharma tariffs take hold, CEO says
Pfizer’s local manufacturing setup is already well positioned in the United States, and the New York-based drugmaker could bring additional resources into the country if pharma import tariffs proposed by President Donald Trump take effect, the company's CEO, Albert Bourla, said Monday.
Pfizer’s local manufacturing setup is already well positioned in the United States, and the New York-based drugmaker could bring additional resources into the country if pharma import tariffs proposed by President Donald Trump take effect, the company's CEO, Albert Bourla, said Monday.
